Endometrial cancer · 12 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Ifosfamide Variant #01 | — | R 12 083 | 21d | — | 48.0 mo | — | — | 1 |
Carboplatin and Paclitaxel (CP) Variant #38 | — | R 5 031 | 21d | — | — | — | — | 1 |
Epirubicin and Paclitaxel (EP) Variant #01 | — | R 3 172 | 21d | — | — | — | — | 1 |
Cisplatin and Doxorubicin N/A - secondary systemic drug | — | R 3 077 | 21d | — | — | — | — | 1 |
Cisplatin and Epirubicin Variant #01 | — | R 2 458 | 21d | — | — | — | — | 1 |
Cisplatin and RT Variant #01 | — | R 1 500 | 49d | ~28.0 mo | — | ~18 | ~R 27 004 PFS proxy · indirect | 8 |
Carboplatin and Doxorubicin Variant #01 | — | R 1 409 | 21d | — | — | — | — | 1 |
CIM Partial | — | — | — | — | — | — | — | — |
Observation Partial | — | — | — | ~20.4 mo | ~38.6 mo | — | — | 4 |
Whole abdominal radiation (WAI) Variant #01 Partial | — | — | — | — | 24.0 mo | — | — | 1 |
Placebo Partial | — | — | — | ~10.2 mo | ~41.1 mo | — | — | 20 |
Radiation therapy N/A - radiation Partial | — | — | 49d | — | — | — | — | 3 |
12 of 12 regimens shown